PTK2 and melanoma: Additionally, we tested the impact of RIPK4 downregulation and upregulation/overexpression on the RIPK4/PEPB1 axis and the RAS/RAF/MEK/ERK and FAK/AKT pathways in melanoma cells carrying V600E and V600D mutations.